Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY545694 in Painful Diabetic Neuropathy
NCT00785577Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of dasolampanel etibutil in diabetic peripheral neuropathy (DPN) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Weekly Mean 24-hour Average Pain Severity Score at 5 weeks. Started Nov 2008; status: completed.
02
Drugs
dasolampanel etibutil
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00785577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785577.